The combination of API with oxaliplatin exerts a significant impact on non-small cell lung cancer (NSCLC) by modulating the EGFR and its downstream signaling pathways (Ji et al., 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.